---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-038705"
form_type: "8-K"
ticker: "REPL"
cik: "0001737953"
company_name: "Replimune Group, Inc."
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:57:20.480482+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Replimune names Sushil Patel CEO effective April 1; Astley-Sparke becomes Executive Chairman

## Summary
- Dr. Sushil Patel appointed CEO effective April 1, 2024; previously Chief Strategy Officer.
- Philip Astley-Sparke transitions from CEO to Executive Chairman; Dieter Weinand becomes Lead Independent Director.
- Robert Coffin moves to Founder & Chief Scientist advisory role; Paul Bullock promoted to Chief Manufacturing Officer.
- Colin Love (COO) retiring May 31; Pamela Esposito and Tanya Lewis leave executive roles but remain advisors.
- Company on track to submit RP1 BLA in 2H 2024 for anti-PD1 failed melanoma.

## SEC filing metadata
- accession: 0001104659-24-038705
- form_type: 8-K
- ticker: REPL
- cik: 0001737953
- company_name: Replimune Group, Inc.
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/0001104659-24-038705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/tm249769d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-038705
- JSON: https://secwatch.observer/filing/0001104659-24-038705.json
- Plain text: https://secwatch.observer/filing/0001104659-24-038705.txt

## Key facts
- Executive change
  Paul Bullock changed role as chief manufacturing officer at Replimune Group, Inc..
  - Action: promoted
  - Role: chief manufacturing officer
  source text: Paul Bullock, the Company’s current senior vice president, operations and Framingham site head, is being promoted to the Company’s chief manufacturing officer effective April 1, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/0001104659-24-038705-index.htm
- Executive change
  Dr. Sushil Patel was appointed as chief executive officer at Replimune Group, Inc..
  - Action: appointed
  - Role: chief executive officer
  source text: Dr. Sushil Patel, the Company’s current chief strategy officer, has been appointed as the Company’s chief executive officer, effective as of April 1, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/0001104659-24-038705-index.htm
- Executive change
  Dieter Weinand changed role as lead independent director of the Board at Replimune Group, Inc..
  - Action: transitioned
  - Role: lead independent director of the Board
  source text: Dieter Weinand, the Company’s current chair of the Board, will transition into the newly created role of the lead independent director of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/0001104659-24-038705-index.htm
- Executive change
  Tanya Lewis changed role as advisor at Replimune Group, Inc..
  - Action: left executive position
  - Role: advisor
  source text: Tanya Lewis, the Company’s current chief development operations officer, will leave their executive positions and plan to continue to lend their functional expertise in an advisory capacity
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/0001104659-24-038705-index.htm
- Executive change
  Philip Astley-Sparke changed role as executive chairman of the Board at Replimune Group, Inc..
  - Action: transitioned
  - Role: executive chairman of the Board
  source text: Philip Astley-Sparke, the Company’s current chief executive officer, will transition to the role of executive chairman of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/0001104659-24-038705-index.htm
- Executive change
  Dr. Colin Love retired as chief operating officer at Replimune Group, Inc..
  - Action: retired
  - Role: chief operating officer
  source text: Dr. Colin Love, the Company’s current chief operating officer, will retire from the Company, effective May 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737953/000110465924038705/0001104659-24-038705-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.